MX2016007369A - Nuevos anticuerpos anti-dpep3 y metodos de uso. - Google Patents
Nuevos anticuerpos anti-dpep3 y metodos de uso.Info
- Publication number
- MX2016007369A MX2016007369A MX2016007369A MX2016007369A MX2016007369A MX 2016007369 A MX2016007369 A MX 2016007369A MX 2016007369 A MX2016007369 A MX 2016007369A MX 2016007369 A MX2016007369 A MX 2016007369A MX 2016007369 A MX2016007369 A MX 2016007369A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- novel anti
- dpep3 antibodies
- dpep3
- antibodies
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/13—Dipeptidases (3.4.13)
- C12Y304/13019—Membrane dipeptidase (3.4.13.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915321P | 2013-12-12 | 2013-12-12 | |
| PCT/US2014/070110 WO2015089449A2 (en) | 2013-12-12 | 2014-12-12 | Novel anti-dpep3 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007369A true MX2016007369A (es) | 2016-09-08 |
Family
ID=53371972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007369A MX2016007369A (es) | 2013-12-12 | 2014-12-12 | Nuevos anticuerpos anti-dpep3 y metodos de uso. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10189910B2 (enExample) |
| EP (1) | EP3080607A4 (enExample) |
| JP (1) | JP2017500028A (enExample) |
| KR (1) | KR20160097336A (enExample) |
| CN (2) | CN106104273A (enExample) |
| AU (1) | AU2014361856A1 (enExample) |
| BR (1) | BR112016013048A2 (enExample) |
| CA (1) | CA2932476A1 (enExample) |
| CL (1) | CL2016001432A1 (enExample) |
| IL (1) | IL245946A0 (enExample) |
| MX (1) | MX2016007369A (enExample) |
| PE (1) | PE20160993A1 (enExample) |
| PH (1) | PH12016501109A1 (enExample) |
| SG (1) | SG11201604664PA (enExample) |
| WO (1) | WO2015089449A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102553870B1 (ko) | 2014-03-27 | 2023-07-10 | 버드 락 바이오, 인크. | 인간 카나비노이드 1(cb1) 수용체 결합 항체 |
| CA2990076A1 (en) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| US10744205B2 (en) | 2015-06-23 | 2020-08-18 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies |
| WO2017040301A1 (en) | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
| MA43049A (fr) * | 2015-09-30 | 2018-08-08 | Bird Rock Bio Inc | Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1) |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| WO2018005904A2 (en) * | 2016-07-01 | 2018-01-04 | Ludwig Institute For Cancer Research Ltd | Methods and compositions for pdgf-cc inhibition |
| CA3043489A1 (en) | 2016-11-21 | 2018-05-24 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
| WO2018107109A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Novel anti-kremen2 antibodies and methods of use |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| RU2761390C2 (ru) | 2016-12-21 | 2021-12-07 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы |
| EP3634459A4 (en) * | 2017-02-10 | 2021-01-06 | Washington University | ANTIBODIES DIRECTED AGAINST TIP1 AND THEIR PROCEDURES FOR USE |
| JP7140103B2 (ja) * | 2017-03-10 | 2022-09-21 | コニカミノルタ株式会社 | 治療有効性の予測方法 |
| WO2018213680A1 (en) * | 2017-05-19 | 2018-11-22 | Abbvie Stemcentrx Llc | Diagnostic antibodies and methods of use |
| JP7235733B2 (ja) | 2017-06-05 | 2023-03-08 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｄ－１に特異的に結合する抗体、及び使用方法 |
| EP3760641A4 (en) * | 2018-02-27 | 2021-11-24 | Eisai R&D Management Co., Ltd. | MONOCLONAL ANTIBODIES AGAINST APOA4, IMMUNOASSAY AND KIT FOR MEASUREMENT |
| WO2019222178A1 (en) | 2018-05-14 | 2019-11-21 | Nanostring Technologies, Inc. | Chemical compositions and methods of using same |
| AU2019282778A1 (en) | 2018-06-08 | 2020-12-10 | Alector Llc | Anti-Siglec-7 antibodies and methods of use thereof |
| CN113517029A (zh) * | 2020-08-07 | 2021-10-19 | 广东省计划生育科学技术研究所（广东省计划生育专科医院） | 一种调控dpep3提高精液质量的方法 |
| JP7621481B2 (ja) * | 2020-11-13 | 2025-01-24 | アイバイオ， インク． | Ｃｄ２５抗体 |
| WO2023028451A2 (en) * | 2021-08-25 | 2023-03-02 | Ibio, Inc. | Anti-cd-25 antibody |
| JP2025521114A (ja) * | 2022-05-16 | 2025-07-08 | シティ・オブ・ホープ | 抗ｃｄ８４抗体及びその使用 |
| CN116693672B (zh) * | 2023-06-15 | 2025-08-08 | 郑州伊美诺生物技术有限公司 | 抗3型人副流感病毒单克隆抗体及其制备方法和应用 |
| CN119306830B (zh) * | 2023-07-11 | 2025-06-20 | 东莞市朋志生物科技有限公司 | 抗皮质醇抗体、检测皮质醇的试剂和试剂盒 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| WO1999037779A1 (en) | 1998-01-22 | 1999-07-29 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
| DE69907977T2 (de) | 1998-08-27 | 2004-07-22 | Spirogen Ltd., Ryde | Pyrrolobenzodiazepine |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| CA2499300A1 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1419786A1 (en) | 2002-11-13 | 2004-05-19 | Bracco Imaging S.p.A. | Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ATE542821T1 (de) | 2004-03-01 | 2012-02-15 | Spirogen Ltd | 11-hydroxy-5h-pyrroloä2,1-cüä1,4übenzodiazepin- - on derivate als zwischenverbindungen für die herstellung von c2 substituierten pyrrolobenzodiazepinen |
| ES2533695T3 (es) | 2004-03-02 | 2015-04-14 | Seattle Genetics, Inc. | Anticuerpos cargados parcialmente y métodos para su conjugación |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
| WO2006065533A2 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| EP1813614B1 (en) | 2006-01-25 | 2011-10-05 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives |
| PL2032606T3 (pl) | 2006-05-30 | 2014-04-30 | Genentech Inc | Przeciwciała i immunokoniugaty oraz ich zastosowania |
| CN101501187A (zh) | 2006-06-06 | 2009-08-05 | 田纳西大学研究基金会 | 富含赘生干细胞的组合物及包含其的方法 |
| ES2444695T3 (es) * | 2006-06-23 | 2014-02-26 | Alethia Biotherapeutics Inc. | Polinucleótidos y polipéptidos implicados en el cáncer |
| US20080220448A1 (en) | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
| ES2987072T3 (es) | 2006-09-07 | 2024-11-13 | Scott & White Memorial Hospital | Métodos y composiciones basados en conjugados de toxina diftérica-interleucina-3 |
| WO2008082730A2 (en) * | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| AU2008207945A1 (en) | 2007-01-22 | 2008-07-31 | Macrogenics West, Inc. | Human cancer stem cells |
| US7723485B2 (en) | 2007-05-08 | 2010-05-25 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| EP2676678A1 (en) | 2007-07-17 | 2013-12-25 | The General Hospital Corporation | Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| JP5963341B2 (ja) | 2007-09-14 | 2016-08-10 | アムジエン・インコーポレーテツド | 均質な抗体集団 |
| EP2192922A4 (en) * | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
| US20100162416A1 (en) | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| WO2010081171A2 (en) | 2009-01-12 | 2010-07-15 | Cyntellect, Inc. | Laser mediated sectioning and transfer of cell colonies |
| US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| PT2536399T (pt) | 2010-02-21 | 2020-02-06 | Bayer Healthcare Llc | Método para ativação e conjugação de biomoléculas |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| JP5972864B2 (ja) * | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
| CN102971329B (zh) | 2010-04-15 | 2016-06-29 | 麦迪穆有限责任公司 | 用于治疗增殖性疾病的吡咯并苯并二氮杂卓 |
| MX2012011900A (es) | 2010-04-15 | 2013-03-21 | Seattle Genetics Inc | Conjugados de pirrolobenzodiazepina diana. |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| BR112012030311A2 (pt) | 2010-06-08 | 2017-01-24 | Genentech Inc | anticorpo |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| EP2689787A1 (en) | 2010-09-03 | 2014-01-29 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
| US20130259806A1 (en) | 2010-12-09 | 2013-10-03 | David Light | Dimeric molecular complexes with free cysteine residues and conjugates thereof |
| KR101381319B1 (ko) * | 2011-04-06 | 2014-04-04 | 한국생명공학연구원 | 간세포 분화 탐지용 ｄｎａ 메틸화 마커 및 이를 이용한 탐지 방법 |
| WO2013052108A2 (en) * | 2011-10-03 | 2013-04-11 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of ovarian cancer |
| US11135303B2 (en) * | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| AU2013256596A1 (en) * | 2012-05-01 | 2014-10-09 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| EP2905290B1 (en) | 2012-10-05 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Heterodimeric protein composition |
| PT2839860T (pt) | 2012-10-12 | 2019-07-29 | Medimmune Ltd | Pirrolobenzodiazepinas e conjugados das mesmas |
| SG10201706468RA (en) | 2013-02-08 | 2017-09-28 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| JP6660294B2 (ja) | 2013-06-04 | 2020-03-11 | シトムクス セラピューティクス，インコーポレイティド | 活性化可能抗体を結合するための組成物及び方法 |
| BR112016004242A8 (pt) | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
| EP4190809A1 (en) | 2014-02-11 | 2023-06-07 | Seagen Inc. | Selective reduction of proteins |
| US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
-
2014
- 2014-12-12 MX MX2016007369A patent/MX2016007369A/es unknown
- 2014-12-12 SG SG11201604664PA patent/SG11201604664PA/en unknown
- 2014-12-12 KR KR1020167018641A patent/KR20160097336A/ko not_active Withdrawn
- 2014-12-12 EP EP14870395.2A patent/EP3080607A4/en not_active Withdrawn
- 2014-12-12 BR BR112016013048A patent/BR112016013048A2/pt not_active Application Discontinuation
- 2014-12-12 PE PE2016000784A patent/PE20160993A1/es unknown
- 2014-12-12 CN CN201480073038.XA patent/CN106104273A/zh active Pending
- 2014-12-12 JP JP2016538019A patent/JP2017500028A/ja active Pending
- 2014-12-12 CN CN201811271990.7A patent/CN109575136A/zh active Pending
- 2014-12-12 CA CA2932476A patent/CA2932476A1/en not_active Abandoned
- 2014-12-12 AU AU2014361856A patent/AU2014361856A1/en not_active Abandoned
- 2014-12-12 WO PCT/US2014/070110 patent/WO2015089449A2/en not_active Ceased
-
2016
- 2016-05-31 IL IL245946A patent/IL245946A0/en unknown
- 2016-06-10 CL CL2016001432A patent/CL2016001432A1/es unknown
- 2016-06-10 PH PH12016501109A patent/PH12016501109A1/en unknown
- 2016-06-13 US US15/181,353 patent/US10189910B2/en not_active Expired - Fee Related
- 2016-10-21 US US15/331,282 patent/US9777071B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20170029530A1 (en) | 2017-02-02 |
| SG11201604664PA (en) | 2016-07-28 |
| BR112016013048A2 (pt) | 2017-09-26 |
| EP3080607A4 (en) | 2017-07-12 |
| JP2017500028A (ja) | 2017-01-05 |
| CA2932476A1 (en) | 2015-06-18 |
| IL245946A0 (en) | 2016-07-31 |
| PE20160993A1 (es) | 2016-10-14 |
| CL2016001432A1 (es) | 2017-03-24 |
| US20170044271A1 (en) | 2017-02-16 |
| WO2015089449A3 (en) | 2015-08-06 |
| US9777071B2 (en) | 2017-10-03 |
| US10189910B2 (en) | 2019-01-29 |
| EP3080607A2 (en) | 2016-10-19 |
| KR20160097336A (ko) | 2016-08-17 |
| PH12016501109A1 (en) | 2016-07-11 |
| CN109575136A (zh) | 2019-04-05 |
| AU2014361856A1 (en) | 2016-06-30 |
| WO2015089449A2 (en) | 2015-06-18 |
| CN106104273A (zh) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500781A1 (en) | Novel anti-claudin antibodies and methods of use | |
| PH12016501109A1 (en) | Novel anti-dpep3 antibodies and methods of use | |
| PH12018501153A1 (en) | Novel anti-claudin antibodies and methods of use | |
| PH12015501846A1 (en) | Novel antibody conjugates and uses thereof | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| SG10201806867VA (en) | Dll3 modulators and methods of use | |
| TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
| PH12014501914B1 (en) | Anti sez6 antibodies and methods of use | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| MX385853B (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr. | |
| PH12015501902A1 (en) | Antibody drug conjugates | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| MX2017011344A (es) | Anticuerpos diseñados de sitio específico y métodos de uso. | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| PH12017501930A1 (en) | Calicheamicin contructs and methods of use | |
| HK1230276A1 (en) | Novel anti-dpep3 antibodies and methods of use | |
| HK1228290A1 (en) | Novel anti-claudin antibodies and methods of use | |
| HK1226641A1 (en) | Novel sez6 modulators and methods of use | |
| HK1238261A1 (en) | Novel anti-mfi2 antibodies and methods of use |